BackgroundGlasgow Prognostic Score GPS has been reported as a powerful prognostic tool for patients with advanced non–small cell lung cancer NSCLC. The aim of this study was to assess the relationship between GPS and prognosis related tumor markers in patients with advanced NSCLC.

MethodsWe included 138 advanced NSCLC patients and twenty healthy controls in the study. GPS was calculated by combined serum C-reactive protein CRP and albumin. Three serum tumor markers, which included cytokeratin 19 fragment antigen 21-1 CYFRA21–1, carcinoembryonic antigen CEA and tissue polypeptide specific antigen TPS, were detected by enzyme-linked immunosorbent assay ELISA. GPS and tumor markers were all assessed before chemotherapy. All patients received at least 2 courses of cisplatin-based chemotherapy. After that, 2 to 5 years follow-up was conducted.

ConclusionsOur results showed GPS were positive correlated with CYFRA21-1, CEA and TPS in patients with advanced NSCLC. However, GPS was more efficient in predicting prognosis of advanced NSCLC than these three single prognosis related tumor markers.